{"disease":{"id":"breakthrough-pain","name":"breakthrough pain"},"drugs":{"marketed":[{"drug_id":"fentanyl-f2","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Breakthrough cancer pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl","indication_name":"Breakthrough cancer pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02899884","title":"Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":3765,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02278601","title":"Comparison of Regimens MPIB, CIPCEA, PCEA","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":839,"lead_sponsor_name":"KK Women's and Children's Hospital","has_results":false},{"nct_id":"NCT06308328","title":"A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis","phase":"","overall_status":"RECRUITING","enrollment_count":718,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06287788","title":"A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04011150","title":"Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"KK Women's and Children's Hospital","has_results":false},{"nct_id":"NCT03895762","title":"Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"A.Menarini Asia-Pacific Holdings Pte Ltd","has_results":false},{"nct_id":"NCT04468490","title":"Treatment of Breakthrough Cancer Pain According to European Guidelines","phase":"","overall_status":"TERMINATED","enrollment_count":131,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT03435120","title":"Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)","phase":"","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Angelini Farmacéutica","has_results":false},{"nct_id":"NCT04713189","title":"Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Lee's Pharmaceutical Limited","has_results":false},{"nct_id":"NCT05531422","title":"Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Lee's Pharmaceutical Limited","has_results":false},{"nct_id":"NCT03669263","title":"A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03809455","title":"Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05053308","title":"Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Seoul National University","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}